BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21788469)

  • 1. Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures.
    Cushion MT; Collins MS
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4513-8. PubMed ID: 21788469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production.
    Marcos-Zambrano LJ; Escribano P; Bouza E; Guinea J
    Med Mycol; 2016 Feb; 54(2):155-61. PubMed ID: 26543157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
    Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.
    Cantón E; Pemán J; Valentín A; Espinel-Ingroff A; Gobernado M
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3108-11. PubMed ID: 19380590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
    Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
    J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2009 Oct; 47(10):3323-5. PubMed ID: 19710267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.
    Fleischhacker M; Radecke C; Schulz B; Ruhnke M
    Eur J Clin Microbiol Infect Dis; 2008 Feb; 27(2):127-31. PubMed ID: 18057972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
    Antachopoulos C; Meletiadis J; Sein T; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2008 Jan; 52(1):321-8. PubMed ID: 17938191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.
    Lockhart SR; Zimbeck AJ; Baddley JW; Marr KA; Andes DR; Walsh TJ; Kauffman CA; Kontoyiannis DP; Ito JI; Pappas PG; Chiller T
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3944-6. PubMed ID: 21670187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskov A; Ramani R
    J Clin Microbiol; 2008 Jul; 46(7):2155-9. PubMed ID: 18463213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.
    Cantón E; Espinel-Ingroff A; Pemán J; del Castillo L
    Antimicrob Agents Chemother; 2010 May; 54(5):2194-7. PubMed ID: 20145083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.
    Fiori B; Posteraro B; Torelli R; Tumbarello M; Perlin DS; Fadda G; Sanguinetti M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3031-5. PubMed ID: 21422210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Echinocandins in Candida Biofilm-Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems.
    Ghannoum M; Roilides E; Katragkou A; Petraitis V; Walsh TJ
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S618-21. PubMed ID: 26567279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.